Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Valeant takes over US rights to Eisai Targretin

PBR Staff Writer Published 22 February 2013

Valeant Pharmaceuticals has obtained US rights to Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai.

Under the transaction, Eisai earns $65m upfront payment in addition to probable milestone-based contingent payments.

The new drug application (NDA) for Targretin was transferred to Valeant, which will be responsible for all regulatory requirements related to the product in the US.

Eisai holds Targretin rights outside of the US.

Targretin (bexarotene) capsules and Targretin gel are indicated for patients with skin problems associated with cutaneous T-cell lymphoma (CTCL) when at least one systemic therapy has not worked.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.